Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.54 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | GHSR | Q92847 | 10/20 | 0.44 |
| ▸ | DRD1 | P21728 | 3/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethane SCHEMBL29233312 | 0.90 | ESR2 (0.54) | ESR2GHSRESR1 | |
| SCHEMBL3069653 | 0.90 | ESR2 (0.54) | ESR2GHSRESR1 | |
| SCHEMBL3294838 | 0.88 | ESR2 (0.52) | ESR2NR1H2GHSRNPC1RAB9A | |
| SCHEMBL15605812 | 0.87 | GHSR (0.47) | ESR2NR1H2GHSRACENPC1 | |
| SCHEMBL4481872 | 0.85 | ESR2 (0.49) | ESR2NR1H2GHSRESR1 | |
| SCHEMBL21470624 | 0.85 | ESR2 (0.56) | ESR2NR1H2GHSRDRD1HTR2A | |
| SCHEMBL21470623 | 0.85 | ESR2 (0.56) | ESR2NR1H2GHSRDRD1HTR2A | |
| SCHEMBL3607650 | 0.85 | GHSR (0.44) | ESR2NR1H2GHSRACE | |
| SCHEMBL3604525 | 0.84 | GHSR (0.50) | ESR2GHSR | |
| SCHEMBL3614996 | 0.84 | DRD2 (0.45) | ESR2NR1H2GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6486174-B2 | TREATMENT OF TUMOR GROWTH, METASTASIS, RESTENOSIS, OSTEOPOROSIS, INFLAMMATION, MACULAR DEGENERATION, DIABETIC RETINOPATHY, RHEUMATOID ARTHRITIS, SICKLE CELL ANEMIA, NERVE SYSTEM DISORDERS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-11-26 | — | — | US | disclosed |
| US-20020061885-A1 | Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | disclosed |
| US-20020037897-A1 | Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-03-28 | — | — | US | disclosed |
| WO-2002012193-A1 | TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACID ALKOXYGUANIDINES AS INTEGRIN ANTAGONISTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037897-A1 | Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists | ADGRE5, ITGAL, VCAM1 | ESR2 458/4885NR1H2 697/4885GHSR 295/4885 |
| US-20020061885-A1 | Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists | ITGAL, ITGAV, ITGB3 | ESR2 606/4885NR1H2 624/4885GHSR 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.